We are monitoring the impact of COVID-19 on North America Bipolar Disorder Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 7945
Share on
Share on

North America Bipolar Disorder Market Research Report- Segmented By Type, Mechanism Of Action, Drug Class and Country (the United States, Canada and Rest of North America) – Industry Size, Share, Trends and Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 7945
Pages: 145

North America Bipolar Disorder Market Size (2021 to 2026)

The size of the Bipolar Disorder Market in North America was valued at around USD 2.60 billion in 2021 and is estimated to grow at a CAGR of 2.45% to reach USD 2.94 billion by 2026. 

A person with the disorder deals with drastic mood swings from high mania to extreme lows(depression). Bipolar disorder was once referred to as a manic depression. It is to be treated for a lifetime.

Disasters such as pandemic always lead to more psychological casualties than physical. COVID- 19 pandemic has strongly impacted the mental health issues. It has created a lot of uncertainty for individuals with Bipolar Disorder. The pandemic certainly preponed the growth of the North American Bipolar disorder market. The rise in awareness programs and increased drug productions drive up the Bipolar disorder market in North America.

Accessibility of treatment options and technological advancements that encourage the exact exposure of the patient’s mood and mental state impels the market growth. Innovations in technology lead to the integration of drugs, and therapies are propelling market growth. 2.8% of the adults in the US are diagnosed with bipolar disorder, and 4.4% have undergone at some point in their lives, according to the National Institute of Mental Health (NIMH). The existence of a well-developed hospital and diagnostic center network, high rate of diagnosis, transparent process for profitable reimbursements, and great attention to research and development are fueling the growth in the region. With the surge in healthcare expenditure, the US spends around 3.2$ trillion or 17% of the GDP and serves the best infrastructure and solutions in technology for the patients in this region.

The main problem that currently restricts market growth is a lack of proper facilities to diagnose the disorder. Lack of widespread awareness and strict government rules on misdiagnosis and inadequate technology causes the disorder to be considered another personality disorder or depression. Series competition to manufacture bipolar disorder drugs tends to impact on Bipolar disorder market. However, side effects caused by the drugs and misdiagnosis of the disease tend to restrict the market's growth.

This research report on the North America Bipolar Disorder Market has been segmented and sub-segmented into the following categories:

 By Type:

  • Bipolar I Disorder
  • Bipolar II Disorder
  • Cyclothymic Disorder

By Mechanism of Action:

  • Monoamine Oxidase Inhibitors
  • Tricyclic Antidepressants
  • Benzodiazepines
  • Serotonin-norepinephrine Reuptake Inhibitors
  • Beta-Blockers
  • Selective Serotonin Reuptake Inhibitors
  • Others

By Drug Class:

  • Antianxiety Drugs
  • Mood Stabilizers
  • Antidepressant Drugs
  • Antipsychotic Drugs
  • Anticonvulsants

By Country:

  • The United States
  • Canada
  • Rest of North America

Regionally, North America is predicted to rule the global bipolar disorder market during the forecast period due to various government projects and campaigns to create awareness, leading to a surge in the bipolar disorder market in North America. High-stress levels, Y-O-Y growth in the incidence of bipolar disorders, and inadequate sleep, and the tendency of substance abuse among the people are fuelling the market growth in the region.

The United States market is anticipated to dominate the bipolar disorder market in the region. It is accounted to have 80% of the share alone in North America due to the existence of better healthcare infrastructure. 1 in 5 adults undergoes mental ailments in a year in the US, according to a report published by the National Alliance on Mental Illness. The increasing number of mergers and acquisitions among drug manufacturing companies is a key factor stimulating bipolar disorder in the region.

Canada is right next to the U.S. and the second most promising region in the North American market due to an increase in awareness regarding the diagnosis and treatment of bipolar disorders, and unsatisfied demands in treating disorders are some of the major factors escalating the market growth.

Major companies in the North America bipolar disorder market are Gedeon Richter, Indivior, AstraZeneca, Janssen Pharmaceuticals, Lundbeck, Bristol-Myers Squibb, Ostuca Holdings Co. Ltd., Glaxo SmithKline (GSK), Allergan Plc, Pfizer, Inc and AbbVie, Inc.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Method                       

                                5.1.1 Introduction           

                                5.1.2 Genotypic               

                                5.1.3 Proteomics-based               

                                5.1.4 Phenotypic             

                                5.1.5  Y-o-Y Growth Analysis, By Method              

                                5.1.6  Market Attractiveness Analysis, By Method            

                                5.1.7  Market Share Analysis, By Method             

                5.2 Application                 

                                5.2.1 Introduction           

                                5.2.2 F&B            

                                5.2.3 Diagnostic

                                5.2.4 Pharmaceutical     

                                5.2.5 Environmental       

                                5.2.6 Y-o-Y Growth Analysis, By Application         

                                5.2.7 Market Attractiveness Analysis, By Application       

                                5.2.8 Market Share Analysis, By Application        

                5.3 Product                        

                                5.3.1 Introduction           

                                5.3.2 Identification Services        

                                5.3.3 Consumables         

                                5.3.4 Instruments           

                                5.3.5 Y-o-Y Growth Analysis, By Products and Services   

                                5.3.6  Market Attractiveness Analysis, By Products and Services

                                5.3.7  Market Share Analysis, By Products and Services  

                5.4 End User                      

                                5.4.1 Food Manufacturing Industries      

                                5.4.2 Pharmaceutical Companies              

                                5.4.3 Hospitals and Diagnostic Centres   

                                5.4.4 Other End users    

                                5.3.5 Y-o-Y Growth Analysis, By End User             

                                5.3.6  Market Attractiveness Analysis, By End User          

                                5.3.7  Market Share Analysis, By End User            

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Method

                                                6.1.3.3 By Application

                                                6.1.3.4 By Product

                                                6.1.3.5 By End User

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Method

                                                6.1.4.3 By Application

                                                6.1.4.4 By Product

                                                6.1.4.5 By End user

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Method

                                                6.1.5.3 By Application

                                                6.1.5.4 By Product

                                                6.1.5.5 By End user

                6.2 United States                            

                6.3 Canada                         

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Shimadzu Corporation                           

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Dickinson & Company                            

                8.3 Biolog Inc.                   

                8.4 Merck KGaA                               

                8.5 IEH Laboratories & Consulting Group                              

                8.6 Trivitron Healthcare                

                8.7 Laboratory Corporation of America Holdings                               

                8.8 Thermo Fisher Scientific Inc.                               

                8.9 Bruker Corporation                 

                8.10 Charles River Laboratories                 

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of Type, by  Drug type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

                                                                                                                          

  1. North America Bipolar Disorder Market, By Type, From 2021 to 2026 (USD Million)
  2. North America Bipolar I Disorder Market, By Region, From 2021 to 2026 (USD Million)
  3. North America Bipolar II Disorder Market, By Region, From 2021 to 2026 (USD Million)
  4. North America Cyclothymic Disorder Market, By Region, From 2021 to 2026 (USD Million)
  5. North America Bipolar Disorder Market, By Mechanism of Action, From 2021 to 2026 (USD Million)
  6. North America Monoamine Oxidase Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  7. North America Tricyclic Antidepressants Market, By Region, From 2021 to 2026 (USD Million)
  8. North America Benzodiazepines Market, By Region, From 2021 to 2026 (USD Million)
  9. North America Serotonin-norepinephrine Reuptake Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  10. North America Beta-Blockers Market, By Region, From 2021 to 2026 (USD Million)
  11. North America Selective Serotonin Reuptake Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  12. North America Others Market, By Region, From 2021 to 2026 (USD Million)
  13. North America Bipolar Disorder Market, By Drug Class, From 2021 to 2026 (USD Million)
  14. North America Antianxiety Drugs Market, By Region, From 2021 to 2026 (USD Million)
  15. North America Mood Stabilizers Market, By Region, From 2021 to 2026 (USD Million)
  16. North America Antidepressant Drugs Market, By Region, From 2021 to 2026 (USD Million)
  17. North America Antipsychotic Drugs Market, By Region, From 2021 to 2026 (USD Million)
  18. North America Anticonvulsants Market, By Region, From 2021 to 2026 (USD Million)
  19. United States Bipolar Disorder Market, By Type, From 2021 to 2026 (USD Million)
  20. United States Bipolar Disorder Market, By Mechanism of Action, From 2021 to 2026 (USD Million)
  21. United States Bipolar Disorder Market, By Drug Class, From 2021 to 2026 (USD Million)
  22. Canada Bipolar Disorder Market, By Type, From 2021 to 2026 (USD Million)
  23. Canada Bipolar Disorder Market, By Mechanism of Action, From 2021 to 2026 (USD Million)
  24. Canada Bipolar Disorder Market, By Drug Class, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample